#lp_8_1 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #lp_8_1, aggregated by home.social.
-
Ich dachte, die Zulassung hänge noch, aber die Produktion läuft bereits.
"Zulassungsempfehlungen für Comirnaty und Spikevax LP.8.1"
"Aller Voraussicht nach wird es für die Saison 2025/26 wieder neue COVID-19 Impfstoffe geben. Zwei entsprechende Produkte der Firmen BioNtech/Pfizer und Moderna erhielt nun die Zulassungsempfehlung."
#covid #covidisnotover #comirnaty #spikevax #biontech #moderna #lp81 #lp_8_1
-
Ich dachte, die Zulassung hänge noch, aber die Produktion läuft bereits.
"Zulassungsempfehlungen für Comirnaty und Spikevax LP.8.1"
"Aller Voraussicht nach wird es für die Saison 2025/26 wieder neue COVID-19 Impfstoffe geben. Zwei entsprechende Produkte der Firmen BioNtech/Pfizer und Moderna erhielt nun die Zulassungsempfehlung."
#covid #covidisnotover #comirnaty #spikevax #biontech #moderna #lp81 #lp_8_1
-
Ich dachte, die Zulassung hänge noch, aber die Produktion läuft bereits.
"Zulassungsempfehlungen für Comirnaty und Spikevax LP.8.1"
"Aller Voraussicht nach wird es für die Saison 2025/26 wieder neue COVID-19 Impfstoffe geben. Zwei entsprechende Produkte der Firmen BioNtech/Pfizer und Moderna erhielt nun die Zulassungsempfehlung."
#covid #covidisnotover #comirnaty #spikevax #biontech #moderna #lp81 #lp_8_1
-
Ich dachte, die Zulassung hänge noch, aber die Produktion läuft bereits.
"Zulassungsempfehlungen für Comirnaty und Spikevax LP.8.1"
"Aller Voraussicht nach wird es für die Saison 2025/26 wieder neue COVID-19 Impfstoffe geben. Zwei entsprechende Produkte der Firmen BioNtech/Pfizer und Moderna erhielt nun die Zulassungsempfehlung."
#covid #covidisnotover #comirnaty #spikevax #biontech #moderna #lp81 #lp_8_1
-
Ich dachte, die Zulassung hänge noch, aber die Produktion läuft bereits.
"Zulassungsempfehlungen für Comirnaty und Spikevax LP.8.1"
"Aller Voraussicht nach wird es für die Saison 2025/26 wieder neue COVID-19 Impfstoffe geben. Zwei entsprechende Produkte der Firmen BioNtech/Pfizer und Moderna erhielt nun die Zulassungsempfehlung."
#covid #covidisnotover #comirnaty #spikevax #biontech #moderna #lp81 #lp_8_1
-
Wer sich aktuell im #Bremer Raum gegen #Corona impfen lassen möchte, kann dies bei der Apotheke im #Dodenhof tun. Auf eigenen Wunsch unabhängig von den Stinko-Empfehlungen.
Andere Impfstellen konnte ich keine finden, die impfen alle erst ab Herbst wieder …
Viele, die sich noch mit dem Thema beschäftigen, gehen allerdings davon aus, dass sich gerade eine #Sommerwelle aufbaut mit neuer Variante. Ich lasse mich alle 6 Monate impfen.
#ButenUnBinnen #Bremen #CovisIsNotOver #ImpfenSchützt #LP_8_1
-
Here's the latest variant picture for Europe (excluding the UK), to early May.
The LP.8.1.* variant continued to dominate, growing steadily to around 52% frequency.
The presumed next challengers are still at low frequencies but growing – XFG.* to around 10%, and XDV.* (led by NB.1.8.1) to around 6%, and also XFJ.* grew to 5%.
-
Here's the latest variant picture for the United Kingdom, to late April.
The LP.8.1.* variant has taken over dominance, growing steadily to around 57% frequency.
The XEC.* variant has fallen to around 25%.
-
Here's the latest variant picture for the United States, to early May.
The LP.8.1.* variant has peaked and fell back to 52%.
The presumed next challengers are growing – XDV.* (led by NB.1.8.1) to 9% and XFG.* to 8%.
-
Here's the latest variant picture for Europe (excluding the UK), to mid-April.
The LP.8.1.* variant took over dominance, growing steadily to around 43% frequency.
The presumed next challengers are growing – XFG.* and XDV.* (led by NB.1.8.1) to around 6%, and also XFJ.* grew to 4%.
-
Here's the latest variant picture for the United Kingdom, to late April.
The LP.8.1.* variant has taken over dominance, growing steadily to around 50% frequency.
The XEC.* variant has fallen to around 25%.
#COVID19 #UK #XEC #LP_8_1
Report link:
https://mike-honey.github.io/covid-19-genomes/output/Coronavirus%20-%20Genomic%20Sequencing%20-%20report%20UK.pdf -
Here's the latest variant picture for Canada to late April.
The LP.8.1.* variant is now dominant, growing strongly to 56%.
The XEC.* variant has declined to around 18%.
-
Here's the latest variant picture for the United States, to late April.
The LP.8.1.* variant appears to have peaked and fell back to 54%.
The presumed next challengers are growing – XFG.* to 11% and XDV.* (led by NB.1.8.1) to 6%.
-
Here's the latest variant picture with a global scope, to late April.
Growth of the LP.8.1.* variant is holding at around 39%.
XDV.* (led by NB.1.8.1) looks like the next challenger, rising steadily to 13%
-
Here's the latest variant picture for Europe (excluding the UK), to mid-April.
The LP.8.1.* variant took over dominance, growing steadily to around 43% frequency.
The XEC.* variant fell to around 21%.
-
Here's the latest variant picture for the United Kingdom, to late April.
The LP.8.1.* variant has taken over dominance, growing steadily to around 50% frequency.
The XEC.* variant has fallen to around 25%.
#COVID19 #UK #XEC #LP_8_1
🧵
Report link:
https://mike-honey.github.io/covid-19-genomes/output/Coronavirus%20-%20Genomic%20Sequencing%20-%20report%20UK.pdf -
Here's the latest variant picture for Canada to mid-April.
The LP.8.1.* variant is now dominant, growing strongly to 50%.
The XEC.* variant has declined to around 18%.
-
Here's the latest variant picture for the United States, to mid-April.
The LP.8.1.* variant growth continued to around 61%, but may have peaked.
The presumed next challengers – XFG.* and XDV.* (led by NB.1.8.1) are still below 5%.
-
Here's the latest variant picture for New Zealand, to late April.
DeFLuQE variants continue to dominate at around 50-80%
The LP.8.1.* variant is not offering a sustained challenge.
This is a very unusual picture – in most places XEC.* and/or LP.8.1.* have become dominant.
-
Here's the latest variant picture with a global scope, to late April.
Growth of the LP.8.1.* variant appears to have peaked, and fell to around 39%.
XDV.* (led by NB.1.8.1) looks like the next challenger, rising strongly to 11%
-
Here's the latest variant picture for Australia, to mid-April.
XEC.* continues to dominate, but declined quite sharply in early April to around 40%.
LP.8.1.* variant is still struggling for traction below 20%.
The one to watch is XDV.*, driven by it’s latest sub-lineage NB.1.8.1, rising to 11%.
-
Here's the latest variant picture for Europe (excluding the UK), to mid-March.
The XEC.* variant remains dominant, but it has declined to around 35% frequency.
The LP.8.1.* variant grew to around 24%.
-
Here's the latest variant picture for Canada to mid-March.
The XEC.* variant is still dominant but has declined to 30%.
The LP.8.1.* variant is challenging at around 25%, probably overhauling the JN.1.* + DeFLuQE variants.
-
Here's the latest variant picture for the United States, to mid-March.
The LP.8.1.* variant growth resumed, up to around 54%.
The XEC.* variant has declined to around 18%.
-
Here's the latest variant picture for New Zealand, to late March.
DeFLuQE variants continue to dominate at around 40-60%
The LP.8.1.* variant bubbled up to 22%, before falling back in more recent samples.
-
Here's the latest variant picture for Australia, to mid-March.
XEC.* continues to dominate, although fairly flat at around 50-60%.
The LP.8.1.* variant reached 16%, but then slumped to finish around 10%.
-
Here's the latest variant picture with a global scope, to late March.
Growth of the LP.8.1.* variant resumed to around 38%, with the XEC.* variant declining to 29%.
-
Here's the latest variant picture for Europe (excluding the UK), to mid-March.
The XEC.* variant remains dominant, but it has declined to around 32% frequency.
The LP.8.1.* variant grew to around 22%.
-
Here's the latest variant picture for the United Kingdom, to late-March.
The XEC.* variant remains dominant, but it is generally declining to around 50% frequency.
Growth of the LP.8.1.* variant seemed to accelerate in the recent samples, to around 28%.
-
Here's the latest variant picture for Canada to mid-March. Further samples been back-filled from Ontario, for a more complete picture.
The XEC.* variant is still dominant but has declined to 34%.
The LP.8.1.* variant is challenging at around 24%, probably overhauling the JN.1.* + DeFLuQE variants.
There might be some recent rebound in the FLuQE and FLiRT variants, as unfettered variant evolution continues.
-
Here's the latest variant picture for the United States, to mid-March.
The LP.8.1.* variant growth might be wobbling a bit, at around 47%.
The XEC.* variant has declined to around 21%.
-
Here's the latest variant picture for Australia, to mid-March.
XEC.* continues to dominate, although fairly flat at around 50-60%.
The LP.8.1.* variant grew to around 17%, challenging the DeFLuQE variants as the new heir-apparent. It’s growth trajectory is quite slow.
-
Here's the latest variant picture with a global scope, to mid- March.
Growth of the LP.8.1.* variant seemed to plateau at around 34%, with the XEC.* variant declining to 30%. Recent sample sizes are smaller so this might not be representative.
-
Here's the latest variant picture for Europe (excluding the UK), to early March.
The XEC.* variant remains dominant, but it has declined to around 31% frequency.
The LP.8.1.* variant grew to around 23%.
Note the recent sample volumes are very low, so this might not be a representative picture.
-
Here's the latest variant picture for New Zealand.
DeFLuQE variants continue to dominate, with XEC.* struggling to break above 40%.
This is quite an unusual picture as XEC.* is already dominant in most places.
The LP.8.1.* variant has mostly been below 10%.
-
Here's the latest variant picture for New Zealand.
DeFLuQE variants continue to dominate, with XEC.* seeming to be in decline.
This quite an unusual picture as XEC.* is already dominant in most places.
The LP.8.1.* variant grew to around 12%.
-
Here's the latest variant picture for New Zealand.
DeFLuQE variants continue to dominate, although XEC.* is now challenging.
This quite an unusual picture as XEC.* is already dominant in most places.
The new LP.8.1.* variant is present, but is still at low frequency (around 10%).
-
Here's the latest variant picture for New Zealand.
DeFLuQE variants continue to dominate, although XEC.* is now challenging.
This quite an unusual picture as XEC.* is already dominant in most places.
The new LP.8.1.* group of variants is present, but is still at low frequency (around 10%).
-
Here's the latest variant picture for New Zealand.
DeFLuQE variants continue to dominate, although XEC.* might be growing in recent samples. We can’t be certain with such small sample sizes.
This quite an unusual picture as XEC.* is already dominant in most places.
The new LP.8.1.* group of variants is present, but is still at low frequency (around 5%).